SteroCore

SteroCore is a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapies for cardiorenal and endocrine diseases. The company's lead program, SC-001, is a highly selective mineralocorticoid receptor antagonist (MRA) designed to treat conditions such as primary aldosteronism and chronic kidney disease. By optimizing the selectivity and potency of its candidates, SteroCore aims to overcome the limitations of current MRA therapies, particularly the risk of hyperkalemia. Headquartered in Israel, the company is supported by leading venture capital firms including Pontifax and Arkin Bio Ventures. SteroCore is advancing its pipeline through clinical trials to provide robust efficacy in blood pressure control and organ protection. The company leverages deep expertise in steroid chemistry to address significant unmet needs in the global healthcare market.